37 research outputs found
Dynamic arterial elastance to predict arterial pressure response to volume loading in preload-dependent patients
Journal Article;INTRODUCTION
Hemodynamic resuscitation should be aimed at achieving not only adequate cardiac output but also sufficient mean arterial pressure (MAP) to guarantee adequate tissue perfusion pressure. Since the arterial pressure response to volume expansion (VE) depends on arterial tone, knowing whether a patient is preload-dependent provides only a partial solution to the problem. The objective of this study was to assess the ability of a functional evaluation of arterial tone by dynamic arterial elastance (Ea(dyn)), defined as the pulse pressure variation (PPV) to stroke volume variation (SVV) ratio, to predict the hemodynamic response in MAP to fluid administration in hypotensive, preload-dependent patients with acute circulatory failure.
METHODS
We performed a prospective clinical study in an adult medical/surgical intensive care unit in a tertiary care teaching hospital, including 25 patients with controlled mechanical ventilation who were monitored with the Vigileo(Âź) monitor, for whom the decision to give fluids was made because of the presence of acute circulatory failure, including arterial hypotension (MAP â€65 mmHg or systolic arterial pressure <90 mmHg) and preserved preload responsiveness condition, defined as a SVV value â„10%.
RESULTS
Before fluid infusion, Ea(dyn) was significantly different between MAP responders (MAP increase â„15% after VE) and MAP nonresponders. VE-induced increases in MAP were strongly correlated with baseline Ea(dyn) (r(2) = 0.83; P 0.89 predicted a MAP increase after fluid administration with a sensitivity of 93.75% (95% CI, 69.8%-99.8%) and a specificity of 100% (95% CI, 66.4%-100%).
CONCLUSIONS
Functional assessment of arterial tone by Ea(dyn), measured as the PVV to SVV ratio, predicted arterial pressure response after volume loading in hypotensive, preload-dependent patients under controlled mechanical ventilation.Ye
Brachial artery peak velocity variation to predict fluid responsiveness in mechanically ventilated patients
Journal Article;ClinicalTrials.gov ID: NCT00890071INTRODUCTION
Although several parameters have been proposed to predict the hemodynamic response to fluid expansion in critically ill patients, most of them are invasive or require the use of special monitoring devices. The aim of this study is to determine whether noninvasive evaluation of respiratory variation of brachial artery peak velocity flow measured using Doppler ultrasound could predict fluid responsiveness in mechanically ventilated patients.
METHODS
We conducted a prospective clinical research in a 17-bed multidisciplinary ICU and included 38 mechanically ventilated patients for whom fluid administration was planned due to the presence of acute circulatory failure. Volume expansion (VE) was performed with 500 mL of a synthetic colloid. Patients were classified as responders if stroke volume index (SVi) increased >or= 15% after VE. The respiratory variation in Vpeakbrach (DeltaVpeakbrach) was calculated as the difference between maximum and minimum values of Vpeakbrach over a single respiratory cycle, divided by the mean of the two values and expressed as a percentage. Radial arterial pressure variation (DeltaPPrad) and stroke volume variation measured using the FloTrac/Vigileo system (DeltaSVVigileo), were also calculated.
RESULTS
VE increased SVi by >or= 15% in 19 patients (responders). At baseline, DeltaVpeakbrach, DeltaPPrad and DeltaSVVigileo were significantly higher in responder than nonresponder patients [14 vs 8%; 18 vs. 5%; 13 vs 8%; P 10% predicted fluid responsiveness with a sensitivity of 74% and a specificity of 95%. A DeltaPPrad value >10% and a DeltaSVVigileo >11% predicted volume responsiveness with a sensitivity of 95% and 79%, and a specificity of 95% and 89%, respectively.
CONCLUSIONS
Respiratory variations in brachial artery peak velocity could be a feasible tool for the noninvasive assessment of fluid responsiveness in patients with mechanical ventilatory support and acute circulatory failure.
TRIAL REGISTRATION
ClinicalTrials.gov ID: NCT00890071.Ye
Non-invasive assessment of fluid responsiveness by changes in partial end-tidal CO2 pressure during a passive leg-raising maneuver
The age of black pine (Pinus nigra Arn. ssp. salzmannii (Dunal) Franco) mother trees has no effect on seed germination and on offspring seedling performance
Key message: We sampled Pinus nigra cones in 29 trees in an age range of 90 to 725 years. The mother tree age did not significantly influence the pinecone or pine seed size, seed germination capacity, or plant size or vigor displayed during the first year of growth in the nursery.
Context: Pinus nigra Arn. ssp. salzmannii is a long-lived Mediterranean species, with millenary trees residing in an old-growth forest in the Cazorla Mountain Range in SE Spain which is home to the oldest known trees in the Iberian Peninsula.
Aims: This study aimed to assess how the mother tree age in Pinus nigra influences seed viability, germination capacity, and the seedling survival and growth during the first year under nursery conditions.
Methods: Twenty-nine trees aged 90 to 725 years were selected and 60 cones were harvested per tree to study the cone characteristics (size and weight), seed viability, and germination capacity in relation to the mother tree age. Eighty germinated seeds per tree were transferred to the nursery and seedling survival and growth were measured after the first growing season.
Results: Significant between-tree differences were detected for cone characteristics (cone and seed weight, number of seeds per cone), as well as for germination capacity. Notably, however, the mother tree age did not significantly influence the aforementioned parameters.
Conclusion: Forest management and regeneration practices of Pinus nigra should take into account that trees of this species up to at least 725 years old produce seeds with a fairly high reproductive capacity.The dendrochronological fieldwork of this research was funded by the Netherlands Organisation for Scientific Research (NWO-number 236-61-001) and National Geographic Society (Waitts Grant W 329-14). The University of Huelva, Spain, provided the lab and nursery with the needed material to perform the experiment
Why Did Red Ereño Limestone Go Red? Linking Scientific Knowledge and Geoheritage Story-Telling (Basque Country, Spain)
Red Ereño is a red-stained ornamental and construction limestone with characteristic white fossil shells. Although exploited since Roman times, marketed worldwide and that the rock itself and its outcrop areas have been included in geological heritage inventories, the origin of its characteristic reddish colour remained unresolved. The aim of this work is to deepen the scientific knowledge of Red Ereño as a basis for understanding the characteristics of this stone and to make this information available for geoconservation actions. The mineralogical and petrological study, mainly based on optical and electron microscopy, X-ray diffraction, and rock magnetism and paleomagnetic techniques, concluded that the red-staining mineral is pigmentary hematite. Moreover, the analysis stated that hematite precipitated after sedimentation but prior to burial diagenesis and before alpine inversion. Based on palaeomagnetic studies, it can be stated that mineralisation occurred during the Late Cretaceous. This work illustrates how scientific research on this potential heritage stone provides key information for geoconservation.This study has been carried out by the UPV/EHU Research Group IT-1678/22 (Government of the Basque Country) in the framework of the project US21/32 under the cooperation agreement between the University of the Basque Country UPV/EHU, Basque Energy Agency (EVE), and Provincial Council of Biscay (BFA). Authors also thank the support of the project PID2019-108753GB-C21 financed by State Research Agency (Spain) [AEI /https://doi.org/10.13039/501100011033]. Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. UPV/EHU Research Group IT-1678/22 (Government of the Basque Country); UPV/EHU, EVE/EEE, DFB/BFA project US21/32
Hypotension Prediction Index Software to Prevent Intraoperative Hypotension during Major Non-Cardiac Surgery: Protocol for a European Multicenter Prospective Observational Registry (EU-HYPROTECT)
Intraoperative hypotension is common in patients having non-cardiac surgery and associated with postoperative acute myocardial injury, acute kidney injury, and mortality. Avoiding intraoperative hypotension is a complex task for anesthesiologists. Using artificial intelligence to predict hypotension from clinical and hemodynamic data is an innovative and intriguing approach. The AcumenTM Hypotension Prediction Index (HPI) software (Edwards Lifesciences; Irvine, CA, USA) was developed using artificial intelligence-specifically machine learning-and predicts hypotension from blood pressure waveform features. We aimed to describe the incidence, duration, severity, and causes of intraoperative hypotension when using HPI monitoring in patients having elective major non-cardiac surgery
Hypotension prediction index software to prevent intraoperative hypotension during major non-cardiac surgery: protocol for a european multicenter prospective observational registry (EU-HYPROTECT)
Background: Intraoperative hypotension is common in patients having non-cardiac surgery and associated with postoperative acute myocardial injury, acute kidney injury, and mortality. Avoiding intraoperative hypotension is a complex task for anesthesiologists. Using artificial intelligence to predict hypotension from clinical and hemodynamic data is an innovative and intriguing approach. The AcumenTM Hypotension Prediction Index (HPI) software (Edwards Lifesciences; Irvine, CA, USA) was developed using artificial intelligence-specifically machine learning-and predicts hypotension from blood pressure waveform features. We aimed to describe the incidence, duration, severity, and causes of intraoperative hypotension when using HPI monitoring in patients having elective major non-cardiac surgery.
Methods: We built up a European, multicenter, prospective, observational registry including at least 700 evaluable patients from five European countries. The registry includes consenting adults (?18 years) who were scheduled for elective major non-cardiac surgery under general anesthesia that was expected to last at least 120 min and in whom arterial catheter placement and HPI monitoring was planned. The major objectives are to quantify and characterize intraoperative hypotension (defined as a mean arterial pressure [MAP] < 65 mmHg) when using HPI monitoring. This includes the time-weighted average (TWA) MAP < 65 mmHg, area under a MAP of 65 mmHg, the number of episodes of a MAP < 65 mmHg, the proportion of patients with at least one episode (1 min or more) of a MAP < 65 mmHg, and the absolute maximum decrease below a MAP of 65 mmHg. In addition, we will assess causes of intraoperative hypotension and investigate associations between intraoperative hypotension and postoperative outcomes.
Discussion: There are only sparse data on the effect of using HPI monitoring on intraoperative hypotension in patients having elective major non-cardiac surgery. Therefore, we built up a European, multicenter, prospective, observational registry to describe the incidence, duration, severity, and causes of intraoperative hypotension when using HPI monitoring in patients having elective major non-cardiac surgery.Funding: Edwards Lifesciences SA, Department of Critical Care, Route de lâEtraz 70, 1260 Nyon, Switzerland funded the study and acts as the legal sponsor. The sponsor/funder had an active role in the design of the study. The collection, analysis, and interpretation of the data will be a collaborative effort of all investigators, who will also write the manuscript.
Acknowledgments: We acknowledge the support of all participating patients and their physicians. We also acknowledge the tremendous contribution of the staff at Edwards Lifesciences, especially Edward Hembrow, Tim van den Boom, Anne Halfmann, Pierre Sibileau, Barbara Plasschaert, Volker Haag, Giulia Torricella and Alessia Longo. We further appreciate the excellent project management secured by Daniel Greinert, Marie Zielinksi and Claudia LĂŒske at the Institute for Pharmacology and Preventive Medicine (Cloppenburg, Germany). Data are captured using the s4trials software provided by Software for Trials Europe GmbH (Berlin, Germany)
Frequency, risk factors, and outcomes of hospital readmissions of COVID-19 patients
To determine the proportion of patients with COVID-19 who were readmitted to the hospital and the most common causes and the factors associated with readmission. Multicenter nationwide cohort study in Spain. Patients included in the study were admitted to 147 hospitals from March 1 to April 30, 2020. Readmission was defined as a new hospital admission during the 30 days after discharge. Emergency department visits after discharge were not considered readmission. During the study period 8392 patients were admitted to hospitals participating in the SEMI-COVID-19 network. 298 patients (4.2%) out of 7137 patients were readmitted after being discharged. 1541 (17.7%) died during the index admission and 35 died during hospital readmission (11.7%, p = 0.007). The median time from discharge to readmission was 7 days (IQR 3-15 days). The most frequent causes of hospital readmission were worsening of previous pneumonia (54%), bacterial infection (13%), venous thromboembolism (5%), and heart failure (5%). Age [odds ratio (OR): 1.02; 95% confident interval (95% CI): 1.01-1.03], age-adjusted Charlson comorbidity index score (OR: 1.13; 95% CI: 1.06-1.21), chronic obstructive pulmonary disease (OR: 1.84; 95% CI: 1.26-2.69), asthma (OR: 1.52; 95% CI: 1.04-2.22), hemoglobin level at admission (OR: 0.92; 95% CI: 0.86-0.99), ground-glass opacification at admission (OR: 0.86; 95% CI:0.76-0.98) and glucocorticoid treatment (OR: 1.29; 95% CI: 1.00-1.66) were independently associated with hospital readmission. The rate of readmission after hospital discharge for COVID-19 was low. Advanced age and comorbidity were associated with increased risk of readmission
Effect of viral storm in patients admitted to intensive care units with severe COVID-19 in Spain: a multicentre, prospective, cohort study
Background: The contribution of the virus to the pathogenesis of severe COVID-19 is still unclear. We aimed to evaluate associations between viral RNA load in plasma and host response, complications, and deaths in critically ill patients with COVID-19. Methods: We did a prospective cohort study across 23 hospitals in Spain. We included patients aged 18 years or older with laboratory-confirmed SARS-CoV-2 infection who were admitted to an intensive care unit between March 16, 2020, and Feb 27, 2021. RNA of the SARS-CoV-2 nucleocapsid region 1 (N1) was quantified in plasma samples collected from patients in the first 48 h following admission, using digital PCR. Patients were grouped on the basis of N1 quantity: VIR-N1-Zero ([removed]2747 N1 copies per mL). The primary outcome was all-cause death within 90 days after admission. We evaluated odds ratios (ORs) for the primary outcome between groups using a logistic regression analysis. Findings: 1068 patients met the inclusion criteria, of whom 117 had insufficient plasma samples and 115 had key information missing. 836 patients were included in the analysis, of whom 403 (48%) were in the VIR-N1-Low group, 283 (34%) were in the VIR-N1-Storm group, and 150 (18%) were in the VIR-N1-Zero group. Overall, patients in the VIR-N1-Storm group had the most severe disease: 266 (94%) of 283 patients received invasive mechanical ventilation (IMV), 116 (41%) developed acute kidney injury, 180 (65%) had secondary infections, and 148 (52%) died within 90 days. Patients in the VIR-N1-Zero group had the least severe disease: 81 (54%) of 150 received IMV, 34 (23%) developed acute kidney injury, 47 (32%) had secondary infections, and 26 (17%) died within 90 days (OR for death 0·30, 95% CI 0·16â0·55; p<0·0001, compared with the VIR-N1-Storm group). 106 (26%) of 403 patients in the VIR-N1-Low group died within 90 days (OR for death 0·39, 95% CI 0·26â0·57; p[removed]11 pĂĄgina